Drug News

Testosterone Replacement Therapy Market to Reach $2.9 Billion Globally, By 2032

The Testosterone Replacement Therapy (TRT) market is poised for significant growth, with a projected global value of $2.9 billion by 2032, reflecting a compound annual growth rate (CAGR) of 4.2% from 2023 to 2032. This forecast is based on a recent report titled “Testosterone Replacement Therapy Market” published by Allied Market Research.

Key drivers fueling the growth of the TRT market include:

1.        Prevalence of Hypogonadism: The increasing prevalence of hypogonadism, a condition characterized by low testosterone levels, is a prime determinant of market expansion.

2.        Heightened Awareness of Men’s Health: There’s a growing awareness regarding men’s health and overall well-being, which is driving demand for TRT.

3.        Rise in Geriatric Population: With a surge in the elderly population, there’s an increased need for treatments addressing age-related health issues, including hypogonadism.

The report highlights the dominance of the injectables segment within the TRT market. In 2022, injectables accounted for almost three-fourths of TRT revenue, driven by their cost-effectiveness and high efficiency. However, other segments, particularly those offering prolonged-release implants, are expected to witness rapid growth during the forecast period.

Among active ingredients, testosterone cypionate held the largest share in 2022, owing to its widespread adoption. Nevertheless, the testosterone undecanoate segment is projected to register the highest CAGR, primarily due to its availability in both topical and injectable formulations.

Clinics emerged as the leading end-user segment in 2022, catering to a large male patient base suffering from hypogonadism. Geographically, North America dominated the market in 2022, accounting for nearly half of the TRT revenue, driven by its well-established healthcare infrastructure and the aging population. However, the Asia-Pacific region is expected to witness the highest CAGR during the forecast period, attributed to the increasing incidence of hypogonadism and obesity.

Key players in the TRT market include AbbVie Inc., Besins Healthcare SA, Acerus Pharmaceuticals Corporation, Amneal Pharmaceuticals Inc., Acrux Ltd., Endo International Plc, Biote Medical, LLC, Pfizer Inc., Insud Pharma S.L, and Marius Pharmaceuticals. These companies are employing strategies such as acquisitions to expand their market presence.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker